Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of “Moderate Buy” by Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $38.5385.

VRDN has been the topic of several recent research reports. Royal Bank Of Canada upped their price target on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Truist Financial raised their price objective on shares of Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of Viridian Therapeutics in a research note on Monday, June 29th. Wall Street Zen lowered Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Evercore set a $26.00 price target on Viridian Therapeutics in a report on Friday, May 15th.

Viridian Therapeutics Trading Down 0.2%

NASDAQ:VRDN opened at $22.92 on Friday. Viridian Therapeutics has a 52-week low of $13.18 and a 52-week high of $34.29. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a fifty day simple moving average of $21.11 and a 200-day simple moving average of $20.53. The company has a market capitalization of $2.60 billion, a PE ratio of -6.80 and a beta of 0.97.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.06 million. On average, equities research analysts expect that Viridian Therapeutics will post -4.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Viridian Therapeutics

A number of hedge funds have recently bought and sold shares of VRDN. KBC Group NV acquired a new position in Viridian Therapeutics in the 1st quarter valued at $34,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth $36,000. State of Wyoming purchased a new position in Viridian Therapeutics during the second quarter worth about $43,000. Larson Financial Group LLC purchased a new position in Viridian Therapeutics during the third quarter worth about $52,000. Finally, US Bancorp DE boosted its stake in Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.